OnCusp Therapeutics Reported Positive Ovarian Cancer Data
The company announced promising results from a Phase 1b clinical trial for its antibody-drug conjugate candidate CUSP06.
Updated on Oct. 5, 2026 in Cancer
Live Poll
Do you believe experimental cancer drug treatments are likely to outperform standard current medical options?
OnCusp Therapeutics revealed positive Phase 1b clinical trial data for CUSP06, a treatment candidate for platinum-resistant ovarian cancer. The results, presented at the IGCS 2026 Annual Global Meeting, showed significant response rates in pre-treated patients.
Why it matters
Patients with platinum-resistant ovarian cancer often face limited treatment options due to resistance to traditional chemotherapy. New therapeutic approaches are required to improve outcomes for this difficult-to-treat population.
The Phase 1b study included 86 patients who achieved a 62% objective response rate in the 4.0 mg/kg cohort. Researchers reported a 1% incidence rate of pneumonitis and observed no ocular toxicity across the four dose cohorts.
The players
OnCusp Therapeutics
This Princeton-based biotechnology company focuses on developing targeted cancer therapies.
Multitude Therapeutics
This pharmaceutical organization previously held the development rights for the CUSP06 drug candidate.
The details
CUSP06 functions as an antibody-drug conjugate, combining a CDH6-targeting antibody with a protease-cleavable linker and an exatecan payload. The trial evaluated doses ranging from 3.6 mg/kg to 4.4 mg/kg to determine safety and efficacy profiles.
Timeline
In 2022, OnCusp obtained global rights to develop CUSP06.
September 23, 2026 was the data cutoff for the Phase 1b trial analysis.
October 3, 2026, marked the presentation of data at the IGCS Annual Meeting.
October 5, 2026, was the date the company publicly announced the trial data.
The Big Picture
The clinical progression of CUSP06 follows the regulatory pathway established by the FDA Fast Track designation process, which aims to expedite the development of treatments for serious conditions. This approach helps bridge the gap between early-stage laboratory discovery and necessary pivotal testing.
The trial results suggest a potential future treatment option for patients who have exhausted traditional platinum-based chemotherapy. If approved, this therapy could offer an alternative for those who previously required treatments like mirvetuximab soravtansine.
The takeaway
Advancements in antibody-drug conjugates highlight the industry shift toward highly targeted cancer therapies that minimize off-target toxicity. Patients should consult their oncologists regarding clinical trial eligibility for emerging ovarian cancer treatments.
What happens next
The company expects the CUSP06 program to advance into pivotal-stage clinical testing, though specific timelines for these trials have not been publicly detailed.
Further reading
For more information on current treatment landscapes, explore the Cancer section.
More information
View detailed Clinical trial registration information on the official registry portal.
Live Poll
Do you believe experimental cancer drug treatments are likely to outperform standard current medical options?
